TACE-HAIC combined with tislelizumab and lenvatinib compared to HAIC combined with tislelizumab and lenvatinib in the conversion efficacy of unresectable hepatocellular carcinoma

Abstract

Abstract Objective To evaluate whether transarterial chemoembolization combined with hepatic arterial infusion chemotherapy combined with tislelizumab and lenvatinib can improve the effect of conversion therapy. Background At present, the success rate of transformation therapy for unresectable hepatocellular carcinoma is low. There is an urgent need to develop better treatment options for these patients. Methods the data of 47 patients with unresectable hepatocellular carcinoma were analyzed, including TACE-HAIC combined with tislelizumab and lenvatinib group (n = 20) and HAIC combined with tislelizumab and lenvatinib group (n = 27). The effective rate, conversion rate and adverse events of the two groups were compared. Results there was no significant difference in the conversion rate, objective remission rate and disease control rate of TACE-HAIC combined with tislelizumab and lenvatinib in the treatment of unresectable hepatocellular carcinoma (HCC), but there was significant difference in the frequency of conversion therapy (P < 0.0001). TACE-HAIC combined with tislelizumab and lenvatinib significantly reduced the frequency of conversion therapy. In terms of safety, neither group experienced any grade 3–4 AE. TACE-HAIC combined with tislelizumab and lenvatinib group had significantly fewer complications in terms of leukopenia and thrombocytopenia compared to the HAIC combined with tislelizumab and lenvatinib group. Conclusions There was no significant difference in conversion rate, objective remission rate, disease control rate and progression-free survival time between TACE-HAIC combined with tislelizumab and lenvatinib in the treatment of patients with unresectable hepatocellular carcinoma compared with HAIC combined with tislelizumab and lenvatinib. However, it significantly reduces the number of conversion therapy, which may reduce the incidence of hematological related complications, which has a certain practicability.